GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
74.22
+1.50 (+2.06%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close72.72
Open73.20
Bid0.00 x 0
Ask0.00 x 0
Day's Range72.51 - 74.38
52 Week Range63.76 - 86.27
Volume7,906,881
Avg. Volume8,216,579
Market Cap96.951B
Beta0.89
PE Ratio (TTM)8.45
EPS (TTM)8.79
Earnings DateFeb 5, 2018 - Feb 9, 2018
Forward Dividend & Yield2.08 (2.86%)
Ex-Dividend Date2017-12-14
1y Target Est85.70
Trade prices are not sourced from all markets
  • MarketWatch12 hours ago

    Republican tax bill makes big winners of Amgen, Gilead and other drugmakers

    Of all U.S. companies, drugmakers have some of the most cash held outside the country.

  • Is Gilead Sciences, Inc. a Buy?
    Motley Fool13 hours ago

    Is Gilead Sciences, Inc. a Buy?

    The answer is a definite...

  • Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
    Business Wire14 hours ago

    Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma

    Kite, a Gilead Company , announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ in patients with refractory large B-cell lymphoma.

  • Reuters14 hours ago

    Gilead's new drug keeps 56 pct of lymphoma trial patients alive

    More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday. Yescarta, approved by the U.S. Food and Drug Administration in October for aggressive large B-cell lymphoma that did not respond to other treatments, is part of a new class known as chimeric antigen receptor T-cell therapies, or CAR-Ts, designed to reprogram the body's own immune cells to recognize and attack malignant cells. Follow-up on 108 patients treated with Yescarta showed that 42 percent remained in remission after a median of 15 months, and 56 percent were still alive, according to research presented in Orlando at the annual meeting of the American Society of Hematology.

  • Capital Cube2 days ago

    ETFs with exposure to Gilead Sciences, Inc. : December 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Gilead Sciences, Inc. Here are 5 ETFs with the largest exposure to GILD-US. Comparing the performance and risk of Gilead Sciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Barrons.com3 days ago

    Gilead Sciences: Look Who's Shopping!

    Shares of Gilead Sciences (GILD) are higher Friday, after it announced its acquisition of Cell Design Labs. Kite Pharma, which Gilead bought earlier this year, already owned some 12% of the firm, so Gilead ...

  • Why Biotech Stocks May Wait A While Before Feeling The Love
    Investor's Business Daily3 days ago

    Why Biotech Stocks May Wait A While Before Feeling The Love

    Beleaguered biotech investors will likely have to wait until 2018 to get some much-needed relief, analysts say.

  • Gilead Sciences to Acquire Cell Design Labs for $567 Million
    Zacks3 days ago

    Gilead Sciences to Acquire Cell Design Labs for $567 Million

    Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.

  • Reuters3 days ago

    Gilead to buy Cell Design Labs for up to $567 mln

    Drugmaker Gilead Sciences Inc said on Thursday it was acquiring privately-held Cell Design Labs Inc for up to $567 million, giving it access to new technology platforms that would help in the development of cancer drugs. The deal strengthens Gilead's focus on CAR-T drugs, a new class of cancer therapies that involve genetically modifying a patient's own immune cells to better recognize and attack cancer. Gilead said it would make an initial upfront payment to Cell Design of about $175 million and additional payments of up to $322 million upon meeting certain milestones.

  • American City Business Journals3 days ago

    Gilead to pop up to $567 million on East Bay 'smart cell' startup

    Launched little more than a year ago to produce cancer-fighting cell therapies just outside a tumor cell's door, an Emeryville company will be bought by biotech powerhouse Gilead Sciences Inc. for up to $567 million. The technologies behind Cell Design Labs Inc. — born out of the work of University of California, San Francisco, Professor Wendell Lim — could boost the effectiveness of so-called CAR-T drugs while decreasing the risk of potential side effects from those groundbreaking treatments. The buyout is structured with Cell Design Labs getting about $175 million upfront and up to $322 million paid out to most of the company's shareholders after hitting undisclosed milestones.

  • MarketWatch3 days ago

    Gilead Sciences to buy Cell Design Labs for $567 million

    Gilead Sciences Inc. said late Thursday it will acquire privately held cellular therapy company Cell Design Labs Inc. for $567 million. The company said it will acquire the 12.2% of Cell Design shares ...

  • Business Wire3 days ago

    Gilead Sciences and Kite to Acquire Cell Design Labs

    Gilead Sciences, Inc. and its cell therapy subsidiary Kite announced today that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms that will enhance research and development efforts in cellular therapy.

  • GlobeNewswire3 days ago

    Gilead Sciences to Acquire Cell Design Labs

    –Demonstrates Gilead’ s Deep Commitment to Cell Therapy–. –Novel Cell Engineering Technologies with the Potential to Drive Discovery and Development of New Anti-Cancer Medicines–. –Structured Buy Out to ...

  • Investopedia4 days ago

    Top 5 Biotech Stocks for 2017

    Biotech can be risky, but these top biotech stocks have stable track records.

  • Why Gilead Could Have 'Greatest' Ever In HIV Drug Launches
    Investor's Business Daily4 days ago

    Why Gilead Could Have 'Greatest' Ever In HIV Drug Launches

    Gilead has a potential GOAT on its hands, an analyst said Wednesday. Its drug, bictegravir, is likely to become the "Greatest Of All Time" among HIV drug launches.

  • Barrons.com5 days ago

    Glaxo Who? Why Gilead's HIV Drug Could Be the 'Greatest of All Time'

    Shares of Gilead Sciences (GILD) are rising Wednesday, helped by a bullish note from Credit Suisse, which argues that its HIV treatment Bictegravir could be a launch that will become "the greatest ...

  • Investopedia6 days ago

    Biotech Stocks May See a New M&A Wave in 2018

    Struggling biotech giants could bolster their stocks in 2018 if they acquire smaller drug companies.

  • American City Business Journals6 days ago

    Gilead Sciences, University of Houston and others launch $100M initiative to address HIV/AIDS crisis in South

    The University of Houston Graduate College of Social Work is among scientific institutions teaming up to take aim at the growing HIV/AIDS crisis in the southern United States. Gilead Sciences Inc. (GILD), Emory University Rollins School of Public Health, the Southern AIDS Coalition and UH on Dec. 4 announced the Gilead Compass Initiative, a $100 million, 10-year commitment of financial resources and support for organizations working to end HIV/AIDS. The South lags behind other parts of the country in terms of HIV prevention and care indicators, according to the Atlanta-based U.S. Centers for Disease Control and Prevention.

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • Business Wire7 days ago

    Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States

    Gilead Sciences, Inc. today announced the launch of the Gilead COMPASS Initiative, a 10-year, $100 million commitment to support organizations working to address the HIV/AIDS epidemic in the Southern United States.

  • 5 Top Biotech Stocks to Buy Now
    Motley Fool8 days ago

    5 Top Biotech Stocks to Buy Now

    Why settle for less when you can buy the best biotech stocks on the market?

  • 3 Drug/Biotech Stocks in Focus on World AIDS Day
    Zacks9 days ago

    3 Drug/Biotech Stocks in Focus on World AIDS Day

    On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.

  • See what the IHS Markit Score report has to say about Gilead Sciences Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILD

  • Investopedia10 days ago

    Why Gilead's Highly Touted Stock Has No Upside

    One investment expert thinks Gilead shares could soar 50%, but there's reason to doubt those projections.

  • The labor market's overheating and the Fed will have to raise 4 times in 2018
    Yahoo Finance Video5 days ago

    The labor market's overheating and the Fed will have to raise 4 times in 2018

    Stocks are weak out of the gate again, with the tech-heavy Nasdaq down the most. In addition to the tax bill making its way through Congress, we just got the ADP numbers this morning showing private companies added added 190,000 jobs in November. Moody's Mark Zandi warning the job market will be overheated next year. Yahoo Finance's Alexis Christoforous and Jared Blikre discuss.